CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Koss Olinger Consulting LLC

Koss Olinger Consulting LLC increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 115.3% in the fourth quarter, Holdings Channel reports. The firm owned 34,168 shares of the company’s stock after purchasing an additional 18,298 shares during the period. Koss Olinger Consulting LLC’s holdings in CRISPR Therapeutics were worth $1,345,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of CRSP. State of New Jersey Common Pension Fund D lifted its stake in CRISPR Therapeutics by 16.8% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 40,341 shares of the company’s stock valued at $1,895,000 after acquiring an additional 5,803 shares during the period. KBC Group NV boosted its holdings in shares of CRISPR Therapeutics by 43.9% in the 3rd quarter. KBC Group NV now owns 2,818 shares of the company’s stock valued at $132,000 after acquiring an additional 860 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of CRISPR Therapeutics by 1.0% in the 3rd quarter. Thrivent Financial for Lutherans now owns 47,696 shares of the company’s stock valued at $2,241,000 after acquiring an additional 473 shares during the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 3.7% in the 3rd quarter. Advisors Asset Management Inc. now owns 9,669 shares of the company’s stock valued at $454,000 after acquiring an additional 342 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $43,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Down 4.3 %

Shares of NASDAQ CRSP opened at $40.97 on Wednesday. The firm has a 50-day simple moving average of $43.04 and a 200-day simple moving average of $45.47. The stock has a market capitalization of $3.51 billion, a price-to-earnings ratio of -9.38 and a beta of 1.76. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares of the company’s stock, valued at $7,673,353.80. This trade represents a 5.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 over the last 90 days. 4.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on CRSP. Bank of America dropped their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. The Goldman Sachs Group dropped their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Stifel Nicolaus dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. Truist Financial boosted their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.